Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler syndrome (MPS-IH), and Wiskott-Aldrich syndrome (WAS).
After receiving feedback from the FDA, the company expects to file a marketing application for OTL-200 in pre-symptomatic, early-onset MLD in late 2022 or early 2023.
The submission of the marketing application in Europe for OTL-103 in WAS has been delayed to 2022 from 2021. The timeline on application submission to the FDA, previously expected in 2022, is not finalized yet.
For OTL-203, Orchard anticipates the initiation of a study in 2022 targeting MPS-IH with a revised trial protocol incorporating the guidance given by the FDA and the European Medicines Agency.
Price Action: ORTX shares are down 3.81% at $4.67 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.